Printer Friendly

ISIS PHARMACEUTICALS TO RECEIVE HIV ANTISENSE PATENT

 ISIS PHARMACEUTICALS TO RECEIVE HIV ANTISENSE PATENT
 CARLSBAD, Calif., Nov. 10 /PRNewswire/ -- Isis Pharmaceuticals, Inc.


(NASDAQ: ISIP) announced today that it will be issued a United States patent on antisense oligonulceotide inhibitors of the human immunodeficiency virus (HIV), the virus which also causes AIDS. Pharmaceutical compositions containing these oligonucleotides are also covered in this patent.
 The patent, U.S. patent 5,166,195, covers phosphorothiate oligonucleotide compositions designed to selectively bind to RNA encoding the HIV tat protein, blocking replication of the virus and the 5' leader sequence, which is common to all HIV RNA transcripts.
 "The tat protein has been studied intensely by numerous research groups and is crucial in the life cycle of the AIDS virus. The 5' leader sequence is important because it is present on all HIV transcripts and the compositions targeting this region show exemplary activation," said Dr. Christopher Mirabelli, senior vice president.
 Isis Pharmaceuticals, Inc., based in northern San Diego County, is engaged in the discovery, development and marketing of novel therapeutic products based on antisense oligonucleotides. Isis is completing Phase I human clinical trials of a new drug, the first antisense drug to be administered to humans, to treat human papillomavirus.
 -0- 11/10/92
 /CONTACT: Christopher Mirabelli, Ph.D., of Isis Pharmaceuticals, Inc., 619-931-9200, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for Isis Pharmaceuticals, Inc./
 (ISIP) CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU:


AH-KW -- NY007 -- 9070 11/10/92 08:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 10, 1992
Words:246
Previous Article:PPG, OTHERS, PLAN CHINA FLOAT GLASS PLANT
Next Article:CLARIS ANNOUNCES CLARISWORKS FOR WINDOWS
Topics:


Related Articles
ISIS PHARMACEUTICALS ANNOUNCES ISSUANCE OF ANTISENSE PATENT
ISIS PHARMACEUTICAL STRENGTHENS PROPRIETARY POSITION WITH FOUR PATENT APPROVALS
ISIS PHARMACEUTICALS RECEIVES FOUR PATENT ALLOWANCES FOR NOVEL ANTISENSE CHEMISTRY
ISIS RECEIVES NOTICE OF ALLOWANCE FOR PATENT FOR INNOVATIVE HIV COMPOUND
ISIS RECEIVES COMPOSITION OF MATTER PATENT ON NOVEL THIRD GENERATION ANTISENSE CHEMISTRY
ISIS RECEIVES PATENT ON ISIS 2302, AN ANTISENSE COMPOUND IN CLINICAL DEVELOPMENT FOR INFLAMMATORY DISEASES
Isis Receives Patent on Antisense Inhibitor of C-raf Kinase, Currently in Phase I Clinical Trials for Cancer
Isis Receives Thirteen Patents Covering Antisense Biology, Chemistry and Combinatorial Chemistry
Isis Pharmaceuticals Receives $7 Million From Drug Royalty USA, Inc.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters